†rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

ACCOUNTSCASHFLOW STATEMENT2000 1998/99(000)DKK(000)DKKCash flow from operating activitiesResult before tax - 57,478 - 54,630Depreciation, provisions and foreign exchangedifferences etc. 481,586 230,684Total 424,108 176,054Change in inventory and receivables - 13,345 14,341Change in payables and other debt 123,851 131,233Paid income taxes - 30,823 - 31,729Total cash flow from operating activities 503,791 288,899* Proceeds from sale of business activities 249,136 0Cash flow from investments:Investments in fixed assets:Intangible fixed assets - 46,322 - 1,117Tangible fixed assets - 80,967 - 46,064Financial fixed assets - 11,699 - 42Total cash flow from investments - 138,988 - 47,223Cash flow from financing:Shareholder´s financing:Proceeds from issuance of share capital 31,102 0External financing:Change in mortgage debt - 6,307 - 8,014Change in long term bank debt - 195,845 - 121Total cash flow from financing - 171,050 - 8,135Cash flow for the year 442,889 233,541Net cash beginning of the year 282,124 48,583Net cash 31. December 725,013 282,124Net cash 31. DecemberCash 759,072 340,789Securities 17,292 18,247Short term bank debt - 51,351 - 76,912Total 725,013 282,124* Proceeds from sale of business activitiesIntangible fixed assets 161,393 0Tangible fixed assets 52,611 0Inventory 35,132 0Total 249,136 0–61–